GW Pharmaceuticals plc, the company licensed by the Home Office to develop cannabis extracts into non-smoked prescription medicines, warmly welcomes the Home Secretary's statement yesterday to the Hom... more
GW is pleased to announce the appointment of David Kirk as Finance Director, with immediate effect. Mr Kirk succeeds Jonathan Laughton who steps down from the Board but will continue in his role of Co... more
GW Pharmaceuticals plc, the company developing a portfolio of prescription medicines derived from cannabis, today announces the first release of preliminary safety and efficacy data from its Phase One... more
GW Pharmaceuticals plc, the company developing a portfolio of prescription medicines derived from cannabis, is commencing clinical trials in Canada. This is the first trial undertaken outside the Unit... more
GW Pharmaceuticals plc ("GW" or "the Company") has noted today's media coverage relating to the findings of a paper by Fiona A Campbell et al* published in the issue of the British Medical Journal ("B... more
GW Pharmaceuticals plc ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces the success... more
GW Pharmaceuticals plc ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces that it has... more
GW Pharmaceuticals ("GW" or "the Company"), a pharmaceutical company developing an innovative range of prescription medicines that harness the medicinal benefits of cannabis, announces that it is plan... more
GW Pharmaceuticals, the company licensed by the UK Home Office to undertake a pharmaceutical research and development programme to develop non-smoked cannabis-based prescription medicines, has obtaine... more
